You searched for "Age-related macular degeneration"
Age-related macular degeneration
1 December 2015
| Nana Theodorou
|
Retina / Uvea / Vitreous
This review article offers an up to date review of the genetic and environmental risk factors associated with aetiology surrounding age-related macular degeneration (AMD). The article briefly describes the typical clinical presentation relating to early and late stages of the...
Exudative age-related macular degeneration
The authors looked at macular lesions in eyes with newly diagnosed exudative age-related macular degeneration. The eyes of 23 patients were included and tested for visual acuity, contrast sensitivity, microperimetry, optical coherence tomography (OCT) and fluorescein and indocyanine green angiography....
The global burden of age-related macular degeneration
1 October 2019
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
Age-related macular degeneration (AMD) is the third leading cause of blindness (behind cataract and refractive error). The authors present the results of the Global Burden of Disease (GBD) 2015 study, which included 195 countries. The disability-adjusted life years (DALY) due...
Age-related macular degeneration in elderly persons in Germany
1 April 2020
| Patty Mopamboli Mboli
|
Retina / Uvea / Vitreous
The authors present the findings of a cross-sectional study in 11 seniors’ community centres. Eleven community centres were screened with a total of 281 participants. A third of participants with gradable images were in normal retinal health (32%).The most common...
Brolucizumab in age-related macular degeneration, HAWK Study
3 October 2023
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
|
Neovascular age-related macular degeneration, aflibercept, anti-vascular endothelial growth factor therapy, brolucizumab, commercial formulation
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
Ranibizumab for the treatment of age-related macular degeneration
1 April 2015
| Nana Theodorou
|
Retina / Uvea / Vitreous
This multicentre randomised prospective open label study compared 0.5 versus 2mg of ranibizumab in patients with submacular retinal pigment epithelial (RPE) detachment due to age-related macular degeneration. Four treatment regimens were used for the two strengths either monthly for 12...
Reduced blood flow and age-related macular degeneration
1 August 2014
| Khadijah Basheer
|
Retina / Uvea / Vitreous
This was a prospective cross-sectional study assessing changes in blood flow velocity in patients with age-related macular degeneration (AMD) using a retinal function imager. Sixty eyes with wet AMD were compared to 53 control eyes and the average blood flow...
Update on emerging therapies for age-related macular degeneration
4 December 2023
| Rod McNeil
|
EYE - Vitreo-Retinal
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...
More sensitive visual acuity test for age-related macular degeneration
1 October 2016
| Roger S Anderson (Prof), Nilpa Shah
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...
Simulating the visual impairment symptoms of age-related macular degeneration in virtual reality
5 June 2023
| Cameron R M Wilson, Ian Underwood, Baljean Dhillon (Prof)
|
EYE - Vitreo-Retinal
A new virtual reality application visually simulates age-related macular degeneration and demonstrates its progression over time including some Charles Bonnet syndrome hallucinations. Introduction Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries with the prevalence of...
Clinical relevance of the anatomic classification of neovascular age-related macular degeneration
The author explains why an OCT-based classification of neovascular AMD is needed and how these neovascular subtypes may help to predict patients’ long-term visual outcome. Age-related macular degeneration (AMD) is a chronic and progressive neurodegenerative process involving the macula in...
